Primary resistance to PD-1/PD-L1 inhibitors in first- or second-line therapy for NSCLC ranges from 21% to 44%, but it could be lowered to 7% to 11% with the addition of chemotherapy [48]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.